Philadelphia, United States
Interius BioTherapeutics is at the forefront of transforming cell engineering by developing innovative techniques to modify cells directly within the human body, as captured in their slogan: "Interius is developing new ways to engineer cells inside the human body, right where they live."
Founded in 2019, the company operates primarily in the Biopharma, Biotechnology, and Health Care industries. Interius BioTherapeutics is headquartered in the United States and has become a part of Kite, a Gilead Company, following a strategic acquisition. Kite Pharma, known for its cutting-edge advancements in cell therapy and headquartered in Santa Monica, California, invested a substantial $350.00M in this acquisition on 01 August 2025.
This acquisition underscores Kite Pharma's commitment to expanding its portfolio in the biopharmaceutical sector by integrating Interius BioTherapeutics' groundbreaking in-body cell engineering technologies into its existing operations to drive future innovations.
